Female sexual dysfunction affects 40% of women and includes low desire (HSDD), arousal difficulties, orgasm problems, and pain during sex. Traditional treatments are limited, but peptides offer new hormone-free options that work through the brain.
This guide covers evidence-based peptide protocols for women's sexual health, including FDA-approved and research options.
| Type | Symptoms | Prevalence | Best Peptides |
|---|---|---|---|
| HSDD (Low Desire) | Lack of sexual thoughts, fantasies, or interest | 10-15% | PT-141, Oxytocin, Kisspeptin |
| Arousal Disorder | Difficulty becoming aroused or maintaining arousal | 15-20% | PT-141, Melanotan-II |
| Orgasmic Disorder | Difficulty achieving orgasm or reduced intensity | 10-15% | Oxytocin, PT-141 |
| Pain Disorders | Pain during intercourse (dyspareunia, vaginismus) | 10-15% | Oxytocin (for anxiety component) |
Female sexual dysfunction is multifactorial:
FDA-approved for premenopausal women with HSDD
Side effects: Nausea (40%), flushing (20%), headache (11%). Take anti-nausea medication 30 minutes before to minimize.
Cost: $900-1,000/month (brand name), $50-150/month (compounded)
Enhances desire through bonding and trust pathways
Best for: Women whose low libido is related to stress, anxiety, or emotional disconnection.
Stimulates natural hormone production
Synergistic effects on arousal and orgasm intensity
Potent arousal enhancement, use with caution
Addressing hormonal and psychological factors
Note: PT-141 is FDA-approved for premenopausal women but used off-label postmenopause with good results.
| Treatment | Efficacy | Side Effects | Cost/Month | FDA Status |
|---|---|---|---|---|
| PT-141 | 60-80% | Nausea (40%), flushing | $50-1,000 | Approved |
| Flibanserin (Addyi) | 10-15% | Dizziness, fatigue | $400-800 | Approved |
| Oxytocin | 30-50% | Minimal | $50-150 | Off-label |
| Testosterone | 40-60% | Virilization, acne | $30-100 | Off-label |
| Kisspeptin | 30-40% | Minimal | $100-200 | Research |